Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
11 déc. 2021 09h00 HE
|
Harpoon Therapeutics
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable...
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
07 déc. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
12 nov. 2021 07h00 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a...
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 nov. 2021 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
09 nov. 2021 16h01 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
04 nov. 2021 09h00 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Change to Management Team and Board of Directors
26 oct. 2021 16h15 HE
|
Harpoon Therapeutics
Julie Eastland Appointed President and Chief Executive Officer Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Scott Myers, Current Member of Harpoon’s Board of...
Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
05 oct. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences
02 sept. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 16h05 HE
|
Harpoon Therapeutics
Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC...